Zhong Guo Jing Ji Wang·2025-09-23 08:37Group 1 - Junshi Bioscience's stock closed at 41.58 yuan, with a decline of 4.26%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share [1] - The highest stock price recorded on the first day of trading was 220.40 yuan [1] Group 2 - The total funds raised from the initial public offering amounted to 4.836 billion yuan, with a net amount of 4.497 billion yuan after deducting issuance costs, exceeding the original plan by 1.797 billion yuan [1] - The planned fundraising amount was 2.7 billion yuan, allocated for innovative drug research and development, industrialization projects, bank loan repayment, and working capital [1] - The issuance costs for the initial public offering were 339 million yuan, including 320 million yuan for sponsorship and underwriting fees [1] Group 3 - In 2022, Junshi Bioscience raised 3.7765 billion yuan by issuing 70 million A-shares at a price of 53.95 yuan per share [2] - After deducting issuance costs of approximately 31.7 million yuan, the actual net amount raised was about 3.7448 billion yuan [2] - The total amount raised from both public offerings is 8.612 billion yuan [2] Group 4 - From 2016 to 2024, the net profit attributable to shareholders showed consistent losses, with figures ranging from -135 million yuan to -2.388 billion yuan [3] - In the first half of 2025, the company reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, but still recorded a net loss of 413 million yuan [3] - The net cash flow from operating activities was -329 million yuan, an improvement from -865 million yuan in the same period last year [3]